Legal Opinion
Janssen Biotech, Inc. v. Celltrion Healthcare Co.
District Court, D. Massachusetts
Decided September 26, 2016No. C.A. No. 15-10698-MLW; 16-11117-MLWPublished
1Opinion of the Court
MEMORANDUM AND ORDER
Wolf, District Judge.
I. SUMMARY
In 2015, plaintiffs Janssen Biotech, Inc. and New York University (collectively “Janssen”) filed Civil Action No. 15-10698 (the “2015 Action”) against defendants Celltrion Healthcare Co., Ltd., Celltrion Inc., and Hospira, Inc. (collectively “Cell-trion”). The case was brought pursuant to the Biologies Price Competition Act (the “BPCIA”), 42 U.S.C. § 262, 35 U.S.a § 271(e)(2)(C). In the 2015 Action, Janssen alleged infringement by defendants’ biosi-milar product of several of Janssen’s patents, including U.S. Patent No. 6,284,471 (the “ ’471‘…
2Cases cited9 opinions
- Catlin v. United StatesSupreme Court of the United States · 1945
- Curtiss-Wright Corp. v. General Electric Co.Supreme Court of the United States · 1980
- Amgen Inc. v. F. Hoffmann-La Roche Ltd.Court of Appeals for the Federal Circuit · 2009
- Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2008
- Gilead Sciences, Inc. v. Natco Pharma LimitedCourt of Appeals for the Federal Circuit · 2014
4 more not listed; retrieve them via the Exa API.